Influence of 1-(alkylamino)silatranes and isoniazid on the antitumor activity of cyclophosphamide in mice bearing Sa 180 tumors.
It was the aim of our investigations to increase the antitumor activity of cyclophosphamide. Therefore we applied a combined treatment with silatranes and isoniazid in relation 1:20:1. The effects were directed against a transplantable sarcoma 180. The parablastomatous invasive zone and the regional lymph nodes draining an implanted tumor were taken for the histochemical and morphological studies. The doses ranged from 50 to 175 mg of body mass. The combined derivatives inhibited tumor growth by 70% in relation to the control. The authors connect the limitation of tumor progression in the applied experimental model in mice with the active response of T dependent zone of the regional lymph nodes, the rebuilding of stroma within the borderline invasive zone and the changes within the composition of cellular immune response of the peritumor tissue.
D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009361:Neoplasm Invasiveness; D017646:Organosilicon Compounds; D012510:Sarcoma 180 / Q000188:drug therapy* / Q000473:pathology; D012825:Silicon / Q000008:administration & dosage / Q000627:therapeutic use*
D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D001952:Bridged-Ring Compounds; D004338:Drug Combinations; D017646:Organosilicon Compounds; C015503:silatrane; D003520:Cyclophosphamide; D007538:Isoniazid; D012825:Silicon